Back to search

Aristotle University Of Thessaloniki (AUTH)

Μελέτη της εξέλιξης της ηπατικής ίνωσης ασθενών με χρόνια ηπατίτιδα Β υπό την επίδραση της αντιικής αγωγής

Abstract

dc:description

Hepatitis B Virus (HBV) infection constitutes one of the major health problems worldwide. Chronic hepatitis B (CHB) affects approximately 400 million people worldwide and continues to be an important cause of morbidity and mortality. CHB often leads to cirrhosis and hepatocellular carcinoma (HCC). The newer antiviral drugs against HBV lead to a complete virological and biochemical remission in the majority of patients with CHB. Long-term antiviral treatment with nucleos(t)ide analogs (NUCs) suppresses HBV replication, delays disease progression and possibly contributes to resolution of fibrosis. The aim of this study was to study the progression of liver fibrosis in patients with CHB. Our hypothesis was that the suppression of HBV-DNA with long-term antiviral therapy, even in patients with advanced fibrosis or cirrhosis, can lead to regression of fibrosis and hepatic architectural improvement in patients with CHB. Patients that were seen at the Hepatology Clinic of the Fourth Unit of Internal Medicine at the Aristotle University of Thessaloniki were included in the study. A prospective and retrospective analysis of patient records with liver biopsy before and after administration of prolonged antiviral therapy (mean follow-up of 6 years) was performed. A total of 53 patients were analyzed. Liver biopsies were performed at baseline and after prolonged antiviral treatment with lamivudine (45/53), adefovir (12/53), tenofovir (9/53) or entecavir (6/53). Because of the development of resistance to lamivudine a nucleot(s)ide analog was added to 20 patients. Furthermore, 23 patients received a 12-month treatment with pegylated interferon-α, followed by nucleos(t)ide analog. In each biopsy, necroinflammatory activity was assessed with the modified histological activity index (HAI), and was classified into 4 categories: 1-minimal (HAI: 0-3); 2-mild (HAI: 4-8); 3-moderate (HAI: 9-12); and 4-severe (HAI: 13-18). Determination of stage was made on Masson trichrome-stained sections using the 5-stage METAVIR system (F0-F4).Twenty-nine patients were male and 24 female. The mean age was 47.2 years. The mean interval between biopsies was 73.8 months. Improvement in activity was observed in 37/53 patients (70%), and in stage in 25/53 patients (47%). Importantly, the repeat biopsies in 6/11 patients with initial stage F4 were classified as F3 (n=4), F2 (n=1) or F1 (n=1). Worsening of stage was observed in only one patient. Development of resistance to lamivudine had no significant effect on stage improvement. Sustained HBV suppression with antiviral treatment in CHB patients leads to reduction of necroinflammatory activity and improvement of stage, regardless of transient viral breakthrough. Potent antivirals in common clinical use for CHB can even lead to regression of fibrous septa and architectural improvement of cirrhotic livers.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papachrysos, Nikolaos
  • Παπαχρυσός, Νικόλαος

Subjects

dc:subject × 12

Rights

dc:rights
Statement dc:rights
  • BY
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/39842

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papachrysos, Nikolaos; Παπαχρυσός, Νικόλαος. Μελέτη της εξέλιξης της ηπατικής ίνωσης ασθενών με χρόνια ηπατίτιδα Β υπό την επίδραση της αντιικής αγωγής. Aristotle University Of Thessaloniki (AUTH), 2017. http://hdl.handle.net/10442/hedi/39842